Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-17-034349

Chief Financial Officer sold 2,500 shares at $17.17 ($42,925)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
RAY DEBANJAN Chief Financial Officer 2017-09-01 Sale −2,500 $17.17 $42,925 17,126 D: show line 1 in the form
Open-market sales · 2,500 sh · avg $17.17 · $42,925
Loading xslF345X03/doc1.xml…